Celsion closed at $2.20 in the latest trading session, marking no change from the prior day. This change was narrower than the S&P 500's daily loss of 0.75%. At the same time, the Dow lost 0.61%, and the tech-heavy Nasdaq lost 0.57%.
Heading into today, shares of the oncology drug development company had gained 7.32% over the past month, outpacing the Medical sector's loss of 4.67% and the S&P 500's gain of 4% in that time.
Investors will be hoping for strength from CLSN as it approaches its next earnings release, which is expected to be May 15, 2019. In that report, analysts expect CLSN to post earnings of -$0.25 per share. This would mark no growth from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $0.13 million, unchanged from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.78 per share and revenue of $0.50 million, which would represent changes of -14.71% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CLSN. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 17.02% higher. CLSN is currently sporting a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CLSN in the coming trading sessions, be sure to utilize Zacks.com.
Image: Bigstock
Celsion (CLSN) Flat As Market Sinks: What You Should Know
Celsion closed at $2.20 in the latest trading session, marking no change from the prior day. This change was narrower than the S&P 500's daily loss of 0.75%. At the same time, the Dow lost 0.61%, and the tech-heavy Nasdaq lost 0.57%.
Heading into today, shares of the oncology drug development company had gained 7.32% over the past month, outpacing the Medical sector's loss of 4.67% and the S&P 500's gain of 4% in that time.
Investors will be hoping for strength from CLSN as it approaches its next earnings release, which is expected to be May 15, 2019. In that report, analysts expect CLSN to post earnings of -$0.25 per share. This would mark no growth from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $0.13 million, unchanged from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.78 per share and revenue of $0.50 million, which would represent changes of -14.71% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CLSN. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 17.02% higher. CLSN is currently sporting a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CLSN in the coming trading sessions, be sure to utilize Zacks.com.